Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
2
Table of Contents
1
Q2 & H1 FY-22
HIGHLIGHTS
2
BUSINESS OVERVIEW
3CAPABILITIES
4 FINANCIALS
5
OUTLOOK
3
Q2 & H1 FY-22 HIGHLIGHTS
Management Speak
SUCHETH DAVULURI
"Our GDS business delivered growth led by the specialty segment. We believe that our sustainable operations amid these uncertain times demonstrates our execution capabilities. We are confident that our
differentiated strategy of delivering differentiated products to our
customers is a competitive advantage which will maximize value for all our stakeholders."
SAHARSH DAVULURI
"Our teams are working closely together to ensure smooth execution of CMS projects. We are happy to see this reflected in the increase in revenues from Development projects. We look forward to commercializing these projects in the future."
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 29 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2021 09:48:01 UTC.
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industryâs chemistry needs. The Company provide solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
NEULAND LABORATORIES LIMITED 
